Giannis Mountzios/X
Mar 26, 2025, 19:20
Giannis Mountzios: ELCC25 MARIPOSA trial – Overall Survival in 1L EGFR-mutant NSCLC
Giannis Mountzios, Director of 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared on X:
“ELCC25 MARIPOSA trial OS in 1L EGFR-mutant NSCLC:
Ami+Laze vs Osi:
- mOS NR vs 36.7 m
- HR 0.79 for CNS progression
- median ic DoR 35.7 months
- projected OS benef> 12 months
- prophylactic anticoagulant and Steroid for iRR
Game changer in 1L. Patients with co-mutations?”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53
Apr 1, 2025, 11:51
Apr 1, 2025, 11:42